CMM and Qiagen Collaborate in Cancer Diagnostics

The Center for Molecular Medicine or CMM has announced the formation of a collaborative effort with its affiliates and Qiagen to support research focused on discovering molecular biomarkers capable of helping diagnose breast cancer and other women’s health issues.

Based on the result of Qiagen’s initial research, the CMM may also provide laboratory-based genomics and proteomics services to assist Qiagen in the development and validation of new molecular diagnostic tests.

Daniel Farkas, executive director of CMM, said: “The speed and analytical depth of XenoBase coupled with the CMM’s access to clinical samples can give Qiagen a competitive advantage in the development of new molecular diagnostic tests, especially in the field of oncology.”